Pharma-Related Probes Could Be Impacted By Departure Of US Attorneys
Executive Summary
Ongoing cases led by New York's Preet Bharara and other US attorneys are unlikely to be affected though their successors could focus on different areas; Boston US Attorney Carmen Ortiz resigned in December.
You may also be interested in...
Insys ‘Reimbursement Unit’ Fraudulently Boosted Fentanyl Rxs, DOJ Charges
Six former Insys executives and managers arrested on changes of misleading insurers and pharmacy benefit managers into authorizing payments for Subsys sublingual fentanyl pain medicine.
Former Valeant, Philidor Execs Charged With Elaborate Kickback Scheme
Specialty mail-order pharmacy Philidor was held up as an example of how Valeant was bilking patients when the usually close arrangement initially came to light; now it seems that Valeant itself was allegedly getting bilked.
Pharma Pricing, Non-Profit Ties Get Increasing Scrutiny From Prosecutors
Off-label marketing and kickbacks may no longer be the top targets of government healthcare fraud investigations as more companies are being hit with subpoenas for pricing information.